U.S. Postal Customs Change Could Disrupt Prescription Shipments From Canadian Pharmacies
In this article & details
U.S. patients who receive prescriptions by mail from Canadian or other international pharmacies may face major delivery interruptions after October 22, 2026. The immediate change is a new U.S. Customs and Border Protection (CBP) postal-entry process—not a statute that expressly bans every personal prescription import.
CBP’s rule changes how low-value international mail is entered and cleared. Whether a medicine is admissible still depends on U.S. Food and Drug Administration (FDA) requirements and case-by-case enforcement discretion. Industry groups expect the combined requirements to make many ordinary mail-order prescriptions unworkable, but the federal rule itself does not name Canadian pharmacies or create a universal prescription-drug ban.
What changes on October 22
CBP’s June 24 interim final rule indefinitely suspends the de minimis administrative exemption for merchandise valued at US$800 or less arriving through the international postal network. It also creates a new informal-entry process for eligible mailed merchandise valued at US$2,500 or less. Several data requirements in that process have an October 22 compliance date, according to the Federal Register notice.
The rule applies broadly to international postal shipments. It does not, on its face, say that all prescriptions from Canada are prohibited. Prescription parcels must still satisfy the laws administered by the FDA and be entered by an eligible party with the required customs information.
FDA policy was already restrictive
The FDA’s personal-importation guidance says that, in most circumstances, individuals may not import drugs for personal use because foreign versions may not be FDA-approved. FDA personnel may consider a more permissive decision in limited situations—for example, where a serious condition lacks an effective domestic treatment, the product is not promoted to U.S. residents, it does not pose an unreasonable risk, and the quantity is generally no more than a three-month supply. These are discretionary considerations, not a blanket entitlement to import.
This means price alone has not been an FDA criterion for allowing personal importation. The October customs change could nevertheless make enforcement more consistent by requiring more information and an eligible importer for mailed goods that previously moved through a simplified low-value pathway.
Why Canadian mail-order pharmacies are warning customers
The Canadian International Pharmacy Association (CIPA) says the interaction between CBP’s new entry requirements, FDA admissibility rules and the available customs-broker arrangements is expected to interrupt most routine personal prescription orders. CIPA describes that outcome as an operational consequence of the combined requirements, even though no government notice declares a universal Canadian-pharmacy ban.
A September 29 KSHB 41 report illustrated the concern through a Kansas City-area couple who had been using an international pharmacy channel to lower the cost of apixaban. They told the station that a three-month international supply had cost roughly what they paid for one month locally. Their pharmacy warned that access could end under the October process.
What this means for Canadian pharmacy practice
The immediate operational exposure is concentrated among Canadian and international pharmacies that dispense to U.S. residents through mail-order channels, their shipping partners and the American patients who depend on those deliveries. The change does not alter how Canadian residents fill prescriptions at Canadian community pharmacies, and it should not be described as a Canadian export prohibition.
Pharmacies serving U.S. patients should verify how their postal operator, broker and compliance advisers will handle pharmaceutical entries after October 22. A parcel accepted by a carrier is not necessarily admissible at the U.S. border. Patients should receive clear, non-alarmist notice about uncertainty, possible delays or refusal, and the need to arrange continuity of care with a U.S.-licensed prescriber and pharmacy.
What happens next
The compliance deadline is October 22, but implementation details may still evolve. CIPA and patient-importation advocates are asking U.S. officials and lawmakers to preserve a workable pathway. Pharmacies should watch for authoritative updates from CBP and FDA rather than relying on headlines that characterize the customs rule as a complete medication ban.
Practice guidance for pharmacists
- Identify affected patients early. Review pending or recurring U.S.-bound mail orders and flag deliveries expected to enter the United States on or after October 22.
- Use precise language. Explain that the change concerns U.S. postal-entry procedures and existing FDA admissibility rules; do not promise that every parcel will be blocked or cleared.
- Verify the shipping pathway. Obtain written direction from the carrier, customs broker and pharmacy compliance adviser about importer-of-record, bonding, data and FDA requirements.
- Support continuity without encouraging stockpiling. Encourage affected patients to contact their U.S. prescriber, insurer and local pharmacy promptly for lawful alternatives and transition planning.
- Document communications. Record notices provided to patients, unresolved shipments, refunds or returns, and any instructions received from logistics partners.
- Monitor primary sources. Recheck CBP’s Federal Register rule, FDA personal-importation guidance and any official implementation notices before changing policy or counselling patients.
